GlassScriptPhysician profile
Madhvendra Singh
NPI 1174590681
$6,855.76
in general payments reported to CMS, 2019-2025
37 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $915 · 2021: $1,127 · 2022: $1,234 · 2023: $978 · 2024: $1,032 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,343.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $715.18 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $683.67 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $624.85 | 2019-2025 | |
| Abbvie INC. | $418.24 | 2021-2024 | Ubrelvy |
| Tolmar, INC. | $298.73 | 2023-2025 | Jatenzo |
| E.R. Squibb & Sons, L.L.C. | $295.45 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $291.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $253.04 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.13 | 2019-2022 | |
| Amarin Pharma, INC. | $182.35 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $173.31 | 2022-2023 | Ingrezza |
| Abbott Laboratories | $135.69 | 2021-2023 | Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $134.47 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $132.64 | 2023-2024 | Gemtesa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $114.63 | 2021-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $100.13 | 2022-2023 | |
| Astellas Pharma US INC | $92.81 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $83.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $67.94 | 2022 | |
| Hologic Sales and Service, LLC | $59.56 | 2019-2021 | |
| Amgen INC. | $51.27 | 2020-2021 | |
| Eisai INC. | $47.36 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $44.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $40.04 | 2021-2023 | Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $37.60 | 2022 | |
| Celgene Corporation | $36.20 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $23.79 | 2021 | |
| Antares Pharma, INC. | $18.89 | 2025 | Xyosted |
| Almatica Pharma LLC | $18.69 | 2021 | |
| Exact Sciences Corporation | $15.41 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $13.86 | 2019 | |
| Esperion Therapeutics, INC. | $13.81 | 2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $13.70 | 2021 | |
| Acerus Pharmaceuticals Corporation | $13.41 | 2022 | |
| Hikma Pharmaceuticals USA | $12.71 | 2021 | |
| Insmed, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhvendra Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.